Publications by authors named "B Kandala"
C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune checkpoint inhibitor efficacy. Preclinical evidence suggests potential benefit of CXCR2 inhibition in multiple solid tumors. In this phase 2 study (NCT03473925), adults with previously treated advanced or metastatic castration-resistant prostate cancer (CRPC), microsatellite-stable colorectal cancer (MSS CRC), or non-small-cell lung cancer (NSCLC) were randomized 1:1 to the CXCR2 antagonist navarixin 30 or 100 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks up to 35 cycles.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic heightened the need for new quantitative tools to quickly assess vaccine safety and efficacy; thus, a model-based meta-analysis (MBMA) was created to analyze both non-clinical and clinical vaccine data.
- A systematic review identified relevant studies, using data from rhesus macaques and human trials to develop predictive models that accurately estimate vaccine efficacy based on serum neutralizing (SN) titres and viral loads.
- The MBMA models showed promising predictive capabilities for vaccine efficacy against SARS-CoV-2, aligning with actual clinical data, thus aiding decision-making in vaccine development based on limited available data.
Background: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support once-weekly dosing.
Setting: A phase 1, open-label, proof-of-concept study was conducted in treatment-naive adults with HIV-1 infection to assess monotherapy antiviral activity.